Introduction
In its recent report to the Federal Government, the Commission of Audit made several recommendations in relation to the Pharmaceutical Benefits Scheme (PBS). 1 These recommendations were based on the premise that current spending on medicines is unsustainable and reform is needed. In particular, the Commission noted that government spending on medicines is expected to be one of the fastest growing areas over the medium to long term. This trend is underpinned by an aging population, the increasing prevalence of chronic disease and the expanding proportion of concessional cardholders. 2 In addition, providing subsidised access to increasingly more personalised medicines and medical technologies has been cited as a contributing factor. 3 However, the notion that Federal Government spending on health care is unsustainable in the long-term remains controversial. Commentators have cited spending in other Organization For Economic Cooperation and Development (OECD) countries as well as the government's latest health spending figures, which show the lowest growth rate since the 1980s, to refute this assumption. 4, 5 Regardless, as the pressure to find savings mounts, health expenditure, which cost Australian governments approximately A$100 billion in 2012-13, 6 remains a prime target. In order to find savings in PBS expenditure, a key recommendation by the Commission was for the Federal Government to adopt a model similar to New Zealand's Pharmaceutical Management Authority (PHARMAC), where an independent authority manages subsidised access to new medicines under a capped budget. However, the opportunity cost of such a decision was not considered, which potentially includes reducing health benefits by limiting subsidised access to new medicines in important disease areas. Using recent research and an updated search for new listings in Australia and New Zealand, the purpose of the present study was to understand current differences in access to new medicines between Australia and New Zealand. In doing so, we question the notion that a capped budget for medicines is a good policy choice for Australia.
The PBS
The PBS is managed by the Department of Health and governed by the National Health Act (NHA) (1953; http://www.comlaw. gov.au/Details/C2014C00353; cited 12 January 2015). The Schedule of Pharmaceutical Benefits (http://www.pbs.gov.au; cited 12 January 2015) lists all medicines that can be dispensed to patients at a subsidised price. To list a new medicine in the Schedule, the Pharmaceutical Benefits Advisory Committee (PBAC) considers the comparative costs and benefits and makes recommendations to the Minister for Health. The PBAC is an independent expert body appointed by the Federal Government and includes doctors, other health professionals, health economists and consumer representatives. 7 
Policy levers to contain expenditure
The Federal Government (henceforth referred to as the Government) has several ways to constrain the fiscal challenge of funding new medicines. We do not provide an assessment regarding the efficacy of these measures; rather, we note those measures that are currently in use by the Government and/or the PBAC.
The NHA (1953) includes a provision that medicines can be listed on one of two formularies (F1 and F2). In general, F1 includes single-branded medicines and F2 includes off-patent medicines with multiple brands. Medicines moving from F1 to F2 incur a statutory price reduction of 16%. For medicines listed in F2, the Government implemented a series of policies over recent years, collectively known as 'price disclosure'. 8 Through sponsors reporting discounts given to pharmacies, 'price disclosure' uses a market-based mechanism to drive down the price the Government pays for F2 medicines. The Government 2013-14 mid-year economic and fiscal outlook noted expenditure on the PBS was lower than expected, due, in part, to higher-thanestimated savings from these pricing policies. 9 The Government has also created therapeutic groups so that groups of medicines in F1 and/or F2 considered 'interchangeable' (judged to provide similar health outcomes) are priced similarly using a weighted average monthly treatment cost (WAMTC) methodology. 10 Regarding new medicines, the Government and PBAC have several other mechanisms to contain expenditure. This includes entering into risk-share agreements with sponsors to ensure expenditure is predictable and contained. Risk-share agreements can include expenditure caps with corresponding rebate arrangements, where sponsors will reimburse government expenditure exceeding forecasts. More recently, the PBAC has recommended 'pay for performance' and outcome-based 'managed entry arrangements', which can include rebates for patients not achieving an agreed clinical outcome, 11 although the feasibility of such arrangements remains untested in practice.
Finally, for both new and existing medicines, the Government can adjust copayments to increase the proportion of drug costs covered by patients, as was proposed in the recent Federal Budget. 12 
New Zealand's PHARMAC
In New Zealand, PHARMAC manages the purchasing of medicines and devices on behalf of District Health Boards (DHBs) for use in the community and, in some cases, within public hospitals.
13 PHARMAC has four main roles: managing the Pharmaceutical Schedule; promoting the responsible use of medicines; managing the funding of medicines and some medical devices used in public hospitals; and managing the Named Patient Pharmaceutical Assessment policy and other special access programs.
Comparing PHARMAC with the PBAC
PHARMAC is a government agency responsible for the management of new and existing subsidised medicines and devices. During the evaluation of new medicines, PHARMAC receives clinical advice from the Pharmacology and Therapeutics Advisory Committee (PTAC). In Australia, the subsidisation of medicines is managed by the Department of Health with advice provided by the PBAC.
There are many similarities and differences between the New Zealand and Australian models for the reimbursement of new medicines. Both take into account cost-effectiveness and budget impact. In order to contain costs, both use therapeutic groups and risk-share arrangements with corresponding caps and rebates for new medicines. However, in contrast with the PBS, PHARMAC operates within a defined funding envelope, which means new medicines can only be listed if there is room in the budgetary cycle. In order to reduce costs, PHARMAC develops 'bundling' deals with sponsors for multiple medicines. Regarding older off-patent medicines, PHARMAC uses a unique tendering process to enter into supply contracts with a single sponsor.
Between countries, the use of a defined funding envelope is a key difference between funding models for new medicines, and we hypothesise this may have contributed to differences in listing outcomes for New Zealand relative to Australia.
Methods
Access to new medicines in Australia and New Zealand has been compared previously.
14 The analysis reviewed subsidised access to new medicines over a 10-year period (2000-09). New medicines were defined as: The analysis showed that 136 new medicines were listed in Australia during the reference period and, of these, 59 were listed in New Zealand.
14 A further summary of results is provided below. Since 2009 we verified the status (as of June 2014) of the 77 new medicines that were listed in Australia and not New Zealand via a review of the PHARMAC 15 and PBS websites. 16 We also performed an additional review of new medicines listed in the previous 12 months (July 2013-June 2014) in both countries via the respective websites.
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Results
Summary of Wonder and Milne 14
Over the study period, 136 new medicines were listed in the Australia Schedule of Pharmaceutical Benefits and 80 new medicines were listed in the New Zealand Pharmaceutical Schedule. Of the 136 new medicines listed in Australia, less than half (n = 59; 43%) were listed in both New Zealand and Australia.
As shown in Fig. 1 , for the 59 common medicines, the mean time from registration to listing was 20.2 months (95% confidence interval (CI) 14.9-25.4 months) in Australia compared with 43.9 months (95% CI 35.6-52.2 months) in New Zealand. The mean difference in the time from registration to listing between Australia and New Zealand was nearly 2 years (mean 23.7 months; 95% CI 14.9-32.4 months). Registration occurred, on average, 9.0 months sooner (95% CI 3.6-14.4 months) in Australia and listing occurred on average 32.7 months earlier (95% CI 24.2-41.2 months) in Australia.
Regarding the 21 new medicines listed in New Zealand but not in Australia during the study period, most were listed in Australia before the study period (n = 16; 76%). Five new medicines (24%) were listed in New Zealand and not in Australia. This includes two medicines that were rejected by the PBAC (ropinirole and anagrelide), one medicine not submitted for reimbursement since 2003 (finasteride), one medicine not registered with the Therapeutic Goods Administration (TGA; pentostatin) and one intrauterine device (levonorgestrel as Mirena, Bayer Australia Ltd, Pymble, NSW, Australia).
The medicines listed in Australia but not New Zealand included seven (9%) treatments for which there was no currently listed therapy, 29 (38%) therapies in a new pharmacological class, 38 (49%) new additions to an existing pharmacological class and three (4%) new presentations for use in a new patient population.
Update on medicine access in New Zealand
Since 2009 we have verified the status of the 77 new medicines that were listed in Australia and not New Zealand. Excluding five medicines subsequently delisted from the PBS (lumiracoxib, efalizumab, anakinra, amprenavir and sitaxentan sodium), 63 of 72 (88%) new medicines listed in Australia between 2000 and 2009 remain unlisted in New Zealand (Table 1) .
Regarding medicines listed from July 2013 to June 2014, there were seven new medicines listed in the New Zealand Pharmaceutical Schedule compared with 18 new medicines listed in the Schedule of Pharmaceutical Benefits (excluding one older medication, namely clobetasol propionate) in Australia ( Table 2) . Of the new medicines listed in Australia, seven were listed via cost-effectiveness and 11 listed via cost-minimisation. Of the seven new medicines listed in New Zealand, six were listed in Australia before July 2013 and the remaining medicine (febuxostat) was rejected by the PBAC in March 2014. Five medicines were listed via cost-effectiveness and one medicine (pegfilgrastim) was listed via cost-minimisation.
Discussion
Both Australia and New Zealand operate similar systems for reimbursing new medicines that take cost-effectiveness and budget impact into account. In order to reduce expenditure, the recent report by the Commission of Audit suggested the Australian system should be reformed to more closely reflect New Zealand's PHARMAC model, 1 where an independent entity manages subsidised access to new medicines under an annual capped budget. The Commission's report did not consider the full opportunity cost of its recommendation.
Previous research of new medicines reimbursed in both Australia and New Zealand shows New Zealand listed fewer than half the new medicines listed in Australia over a 10-year period (2000-09).
14 Our present study shows that the majority of new medicines not listed in New Zealand during this period remain unlisted today. Over the 12 months from July 2013 to June 2014, Australia listed 17 new medicines on the PBS whereas New Zealand listed only one new medicine that was Based on the comparison of funding systems in Australia and New Zealand, we hypothesised that the use of an annual budget cap in New Zealand was likely to lead to a difference in listing outcomes between the two countries, including the number of new medicines and the time to listing. Our results do not directly prove causation, because it is acknowledged that unmeasured confounders may impact funding outcomes, such as funding priorities and specific decision criteria. However, given both countries use similar health technology assessment criteria for new medicines, which rely primarily on the clinical benefit-risk profile in addition to cost-effectiveness and budget impact, it is plausible to assume that a strict annual funding cap in New Zealand limits funding options relative to Australia. This is also verified by previous correspondence from PHARMAC, which highlights the capped annual budget as a key difference between the two systems, and the 'extra care' required to fit expenditure in a budgetary cap may cause 'slower' funding outcomes. 17 Despite the difference in the number of new medicines listed between both countries, our data do not permit an inference between a reduction in new medicines listed and health benefits forgone. Furthermore, because access to medicines is impacted by other factors, such as copayments, we cannot make an inference between a reduction in new medicines listed and community access to medicines in both communities. However, of the medicines not listed in New Zealand over a 10-year period, just under half (n = 36) were part of a new pharmacological class or were for the treatment of a disease with no currently listed medicines (e.g. age-related macular degeneration). Based on our updated outcome data, most of these medicines (n = 30) remain unlisted today. Further, in the 12 months from July 2013 to June 2014, 39% of new medicines listed in Australia were recommended and listed on the basis of acceptable cost-effectiveness. Unlike medicines listed via cost-minimisation, these medicines may yield additional health benefits or provide access to subpopulations not able to use existing medicines. Quantifying the total health impact of not listing these new medicines, relative to standard care, requires further exploration.
The Australian healthcare system is built on equity principles that include providing universal and affordable access to highquality medical, pharmaceutical and hospital services.
18 By using cost-utility analyses, both PHARMAC and the PBAC can ensure health gains are equivalent for each dollar spent on different therapeutic options across different diseases. However, by capping annual expenditure, equity principles are compromised because only a proportion of 'fundable' therapies can be listed within a given budget cycle. In practice, this requires preferencing therapies for funding based on budget capacity, which means specific patient populations will not be able to access new cost-effective therapies until additional funds can be obtained.
Based on the data presented, there is a clear difference in the number of new medicines listed in Australia and New Zealand. Although we cannot definitively link the use of an annual capped budget for medicines to reduced access or health outcomes, our data raise questions regarding the consequences of such a policy. Overall, we believe future reform proposals need to look beyond the cost paradigm to take into account access metrics for new medicines and the downstream effects for the health of the community.
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Febuxostat is the only medicine that that is not listed on the PBS; the rest were first listed on the PBS before 1 July 2013.
